All Stories

  1. Design of polymeric nanocapsules to improve their lympho-targeting capacity
  2. Naturally presented HLA class I–restricted epitopes from the neurotrophic factor S100-β are targets of the autoimmune response in type 1 diabetes
  3. IC-Tagging methodology applied to the expression of viral glycoproteins and the difficult-to-express membrane-bound IGRP autoantigen
  4. Oral hygiene might prevent cancer
  5. BMPR2 gene is overexpressed in lymphoblastoid cell lines from Graves Disease patients
  6. Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest
  7. Apportioning Blame: Autoreactive CD4+ and CD8+ T Cells in Type 1 Diabetes
  8. Human peripheral blood mononuclear cell in vitro system to test the efficacy of food bioactive compounds: Effects of polyunsaturated fatty acids and their relation with BMI
  9. Correction: CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis
  10. Serum dipeptidyl peptidase IV activity and sCD26 concentration in patients with choroidal nevus or uveal melanoma
  11. CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis
  12. Characterization of the autoimmune response against the nerve tissue S100β in patients with type 1 diabetes
  13. Immunology and Immunotherapy of Colorectal Cancer
  14. Stem and immune cells in colorectal primary tumour: Number and function of subsets may diagnose metastasis
  15. Galectin-1 synthesis in type 1 diabetes by different immune cell types: Reduced synthesis by monocytes and Th1 cells
  16. Autoantibodies to glial fibrillary acid protein and S100β in diabetic patients
  17. CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope
  18. CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope
  19. CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope
  20. Role of the capsid protein VP4 in the plasma-dependent enhancement of the Coxsackievirus B4E2-infection of human peripheral blood cells
  21. Tissue-polypeptide-specific antigen levels in diabetic patients with normal and pathological biochemical profiles
  22. HLA Class II molecules on haplotypes associated with type 1 diabetes exhibit similar patterns of binding affinities for coxsackievirus P2C peptides
  23. Identification of a Naturally Processed Cytotoxic CD8 T-Cell Epitope of Coxsackievirus B4, Presented by HLA-A2.1 and Located in the PEVKEK Region of the P2C Nonstructural Protein
  24. Cellular Immune Activation in Gulf War Veterans
  25. Enteroviruses and type 1 diabetes
  26. Characterization of the T-Cell Response to Coxsackievirus B4: Evidence That Effector Memory Cells Predominate in Patients With Type 1 Diabetes
  27. 3β Hydroxysteroid Dehydrogenase Autoantibodies in Patients with Idiopathic Premature Ovarian Failure Target N- and C-Terminal Epitopes
  28. 3  Hydroxysteroid Dehydrogenase Autoantibodies in Patients with Idiopathic Premature Ovarian Failure Target N- and C-Terminal Epitopes
  29. T Cell Activation by Coxsackievirus B4 Antigens in Type 1 Diabetes Mellitus: Evidence for Selective TCR V  Usage Without Superantigenic Activity
  30. T-Cell Reactivity to the P2C Nonstructural Protein of a Diabetogenic Strain of Coxsackievirus B4
  31. Endogenous Enzymatic Activities of the Avian Reovirus S1133: Identification of the Viral Capping Enzyme